DEF 14A: Annovis Bio Seeks Stockholder Approval for Equity Incentive Plan Amendment at 2024 Annual Meeting

Annovis Bio is holding its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on director elections, an amendment to the 2019 Equity Incentive Plan, and ratification of Ernst & Young LLP as the independent auditor.

Summary

• Annovis Bio will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, virtually.
• Stockholders will vote on three proposals: electing five directors, approving an amendment to the 2019 Equity Incentive Plan, and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR all director nominees and both proposals.
• The record date for determining stockholders eligible to vote is April 18, 2024.
• The company had 11,011,299 shares of common stock outstanding as of the record date.
• Directors and executive officers beneficially own approximately 32.3% of the outstanding common stock and are expected to vote in favor of the proposals.
• The company is seeking approval to increase the number of shares authorized under the 2019 Equity Incentive Plan from 2,000,000 to 3,000,000 and increase the maximum number of shares that may be awarded in any one year from 300,000 to 400,000.
• Alliance Advisors has been engaged to assist with proxy solicitation efforts for a fee of $22,375, in addition to expenses.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the Board's recommendations and emphasis on attracting and retaining talent.

Positives

• The Board is actively engaged in corporate governance, with established Audit, Compensation, and Nominating Committees.
• The company is providing stockholders with convenient access to proxy materials online.
• The company is taking steps to ensure compliance with SEC regulations and NYSE listing requirements.
• The company has a clawback policy in place as required by the rules of the NYSE.
• The company has adopted a Code of Business Conduct and Ethics applicable to all of its directors, executive officers and employees.

Negatives

• Directors Bruck, Hoffman, Maccecchini, McCarthy and White and Mr. Hagopian failed to timely file one report with respect to one transaction.
• The company had to restate previously issued condensed financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022 due to a material weakness in internal control over financial reporting.

Risks

• Increased attention on ESG matters, including from customers, shareholders and other stakeholders, may lead to the company expending more resources addressing these issues.
• Legislative and regulatory efforts to combat climate change and address ESG issues may prove costly and burdensome for the company to comply with and will likely continue to impact the company, its customers and its suppliers.
• Climate related changes can increase the frequency and severity of significant weather events and natural disasters.
• The company's insurance may not cover specific losses and the amount of the company's insurance coverage may not be adequate to cover all of its losses.

Future Outlook

The company is seeking to increase the shares reserved for issuance under the Plan as well as the maximum number of awards that may be made in any one year are necessary for the company to continue to offer a competitive equity incentive program.

Management Comments

• Maria Maccecchini, President and CEO, encourages stockholders to vote their shares.
• The Board believes that the Plan will serve a critical role in attracting and retaining the high caliber employees, consultants and directors essential to the company's success and in motivating these individuals to strive to meet the company's goals.

Industry Context

The use of equity incentive plans is a common practice in the biotechnology industry to attract and retain talent, aligning employee interests with those of shareholders.

Comparison to Industry Standards

• Many comparable biotech companies, such as Biogen, Amgen, and Gilead, utilize equity incentive plans to attract and retain key personnel.
• The size of the proposed share increase and individual award limits should be assessed against industry benchmarks to ensure competitiveness.
• The company's corporate governance practices, including board independence and committee structure, appear to align with industry standards.

Related Party Transactions

• On April 7, 2023, the company entered into a subscription agreement with each executive officer and director, pursuant to which the company sold an aggregate of 84,453 shares of its common stock at a price of $12.61 per share, for aggregate proceeds of $1.06 million.
• On November 27, 2023, the company entered into a subscription agreement with certain executive officers and directors, pursuant to which the company sold an aggregate of 207,660 shares of its common stock at a price of $6.10 per share, for aggregate proceeds of $1.27 million.

Stakeholder Impact

• Approval of the equity incentive plan amendment could positively impact employees by providing them with equity-based compensation.
• Approval of the proposals could positively impact shareholders by aligning management's interests with theirs and potentially increasing the company's value.
• The selection of an independent auditor is important for maintaining investor confidence and ensuring the accuracy of financial reporting.

Next Steps

• Stockholders should review the proxy materials and vote their shares before the June 11, 2024 deadline.
• The company will hold the Annual Meeting on June 12, 2024, and announce the voting results in a Form 8-K filing.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, equity incentive plan, Ernst & Young, audit, compensation, governance, Annovis Bio